SCHEMBL3883798

SCHEMBL3883798

CCN(CC)C(=O)c1cccc(CNS(=O)(=O)c2ccc(Cl)cc2)c1

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.65
CYP19A1 P11511 6/20 0.64
LMNA P02545 2/20 0.59
HPGD P15428 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
HTT P42858 1/20 0.59
ALDH1A1 P00352 2/20 0.55
GAA P10253 1/20 0.55
MAPT P10636 1/20 0.55
KMT2A Q03164 1/20 0.53
GPR17 Q13304 1/20 0.53
TBXA2R P21731 3/20 0.49
TBXAS1 P24557 1/20 0.49
LIMK1 P53667 1/20 0.46
LIMK2 P53671 1/20 0.46
MAPK1 P28482 1/20 0.46
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3885277 0.90 HSD11B1 (0.81) HSD11B1LMNAHPGDSMN1; SMN2HTT
SCHEMBL3875065 0.89 HPGD (0.69) HSD11B1CYP19A1LMNAHPGDSMN1; SMN2
SCHEMBL3873566 0.89 HSD11B1 (0.63) HSD11B1CYP19A1LMNAHPGDSMN1; SMN2
SCHEMBL3877107 0.87 HPGD (0.60) HSD11B1CYP19A1LMNAHPGDSMN1; SMN2
SCHEMBL3884161 0.86 CYP19A1 (0.67) HSD11B1CYP19A1LMNAHPGDSMN1; SMN2
SCHEMBL3872241 0.85 LMNA (0.58) HSD11B1CYP19A1LMNAHPGDSMN1; SMN2
SCHEMBL3876577 0.85 CYP19A1 (0.67) HSD11B1CYP19A1LMNAHPGDSMN1; SMN2
SCHEMBL3940044 0.84 LMNA (0.57) HSD11B1CYP19A1LMNAHPGDSMN1; SMN2
SCHEMBL3872431 0.84 HSD11B1 (0.62) HSD11B1CYP19A1LMNAHPGDSMN1; SMN2
SCHEMBL3877412 0.83 CYP19A1 (0.62) HSD11B1CYP19A1LMNAHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814846-B1 11BETA-HSD1 INHIBITORS EVOTEC AG (DE) 2009-04-08 EP disclosed
US-20090069323-A1 11beta-hsdi inhibitors EVOTEC AG (DE) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069323-A1 11beta-hsdi inhibitors HSD3B1, HSD3B2, HSD11B1 HSD11B1 3/4885CYP19A1 23/4885LMNA 2473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.